FDA approves monkeypox vaccine despite acknowledging that it is DANGEROUS

09/25/2024 / By Ava Grace

The Food and Drug Administration (FDA) has approved a vaccine for people deemed to be at “high risk” for monkeypox, despite acknowledging that the injection itself is dangerous.

The regulator approved the ACAM2000 vaccine on Aug. 29. The Defender‘s Suzanne Burdick said in a report that the vaccine was made by Emergent BioSolutions, a company specializing in vaccines for biochemical warfare threats such as anthrax and smallpox. While ACAM2000 was initially approved for smallpox in 2007, the FDA’s recent expanded supplemental approval allows it to be injected into those at “high risk” for monkeypox, such as members of the LGBT community.

According to an FDA press release at the time of its approval, “ACAM2000 is a “live replicating vaccinia virus vaccine.” Even the regulator’s medication guide for the injection admits that it may cause more harm than good. (Related: South African group challenges WHO’s mpox emergency declaration, warns public about vaccine dangers.)

InfoWars reported that the first page of ACAM2000’s medication guide provided by the FDA lists numerous side effects. According to the guide, the live vaccinia virus in the injection “can be spread to individuals who have close contact with the vaccinated individual.” To make matters worse, ACAM2000 “can cause serious complications in vaccinated individuals and in their close contacts to whom the vaccine virus has spread.”

ACAM2000 does more harm than good

Children’s Health Defense senior research scientist Karl Jablonowski denounced the FDA’s approval of ACAM2000 as a “public hazard, not the practice of public health.” He told the Defender: “You can call ACAM2000 a ‘vaccine,’ but its impact on the U.S. will be as a ‘disease.'”

“The spread of vaccinia virus is an infliction and an assault, as an unsuspecting person cannot possibly consent. For good reasons, you would not consent to this vaccine – even if you believed your benefits outweigh your risks – as you become a potential vector of a disease that is damaging to the heart and fatal to both fetus and infant.”

Jablonowski continued that ACAM2000’s package insert reveals that the Department of Health and Human Services (HHS) found roughly 520 per million vaccine recipients who contracted post-vaccination cardiac inflammation – about one in 2,000. But elsewhere in the package insert, the FDA acknowledges that the risk is 5.7 per 1,000 vaccinations – about one in every 175 people.

“If the 262 million adults in the U.S. received this vaccine, an estimated 1.493 million would contract the serious adverse reaction of myopericarditis [i.e. heart lining and/or muscle inflammation],” he remarked.

Internist and biological warfare expert Dr. Meryl Nass said the Centers for Disease Control and Prevention (CDC) also acknowledged the risk of cardiac inflammation in 5.7 per 1,00 primary ACAM2000 vaccinations during a June 2022 meeting.

“It’s a huge number. The fact that the FDA and CDC are acknowledging it means no one should get the vaccine,” she shared.

“Myopericarditis is a life-threatening condition; it lowers your life expectancy. This risk, 1 in 175, is higher than all other licensed vaccines for which the CDC acknowledges side effects. This is the worst.”

Cardiologist Dr. Peter McCullough recounted that HHS Secretary Xavier Becerra declared a monkeypox public health emergency in 2022, but let the declaration expire early in 2023.

“The crisis conjured up little fear for the average American as it was learned that the infection was largely a pustular rash that occurred with intense sexual contact among gay/bisexual men with the skin blisters around the anus and buttocks or mouth,” he wrote in an Aug. 18 post on his Substack.

Head over to MonkeyPoxReport.com for more similar stories.

Watch this video about the effects of the ACAM2000 monkeypox vaccine that the FDA approved in August.

This video is from the Dissident7 channel on Brighteon.com.